Bracco Invests in GMP Manufacturing Facility for Cell Therapy Product Facility upgrades support clinical-grade manufacturing of Bracco’s microbubble-based cell selection and activation technology. GMP readiness expected mid-2027.

Bracco Receives Health Canada Approval for gadopiclenol injection, Advancing Lower-Dose MRI Contrast Imaging

Bracco Receives Health Canada Approval for VUEWAY® injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging

BubbleGen™ Early Access Program Developed by Bracco, BubbleGen™ microbubbles build on more than two decades of use in diagnostic imaging and offer a bead-free alternative to traditional magnetic approaches.

Energy management

BIPSO

Bracco Imaging Earns Second Consecutive EcoVadis Platinum Medal with Record Sustainability Score Recognition reflects Bracco Imaging’s top-tier EcoVadis performance and strengthened sustainability data, governance and procurement practices.

Celltherapy order form

Contact BubbleGen™ Support

Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for for VueJect®, the First Dedicated Ultrasound Contrast Delivery System VueJect® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging